significantly decreased the of placenta-derived mesenchymal stem cells (PL-MSCs) under oxidative stress in a dose-dependent manner.
Fucoxanthin reduces the expression of pro-apoptotic proteins and inhibits their activation in PL-MSCs.
The compound increases the expression of anti-apoptotic proteins in these cells under oxidative stress.
Fucoxanthin downregulates genes associated with endoplasmic reticulum stress and p53-induced apoptosis.
It enhances the expression of genes involved in cell cycle regulation, DNA damage repair, and cytokine signaling.
The findings suggest that fucoxanthin may improve the viability of MSCs in oxidative stress conditions.
Simplified
Human mesenchymal stem cells (hMSCs) hold significant promise in regenerative medicine due to their ability to reduce inflammation and promote tissue repair. However, their therapeutic potential is often compromised by their high susceptibility to under oxidative stress, prevalent in the microenvironment of the target tissues. Our previous study showed that , a carotenoid derived from brown algae, can improve the viability of placenta-derived mesenchymal stem cells (PL-MSCs) by reducing intracellular ROS levels through the activation of the PI3K/Akt/Nrf-2 signaling pathway. In this study, we further investigate the mechanisms underlying the protective effect of fucoxanthin against oxidative stress-induced apoptosis in PL-MSCs, using an in vitro model. PL-MSCs were cultured with 750 µM HOto induce oxidative stress and treated with various concentrations of fucoxanthin for 48 h. The effect of fucoxanthin on PL-MSC apoptosis under oxidative stress conditions was determined using CCK-8, Annexin V/DRAQ7™ apoptosis assays, as well as the expression of apoptosis-related genes and proteins. The effect of fucoxanthin on the transcriptome of PL-MSCs under oxidative stress conditions was also assessed by high-throughput Nanostring analysis. The results showed that fucoxanthin significantly decreased the apoptosis of PL-MSCs under oxidative stress in a dose-dependent manner by reducing the expression of pro-apoptotic proteins and inhibiting their activation, while increasing the expression of anti-apoptotic proteins in these cells. Furthermore, fucoxanthin also downregulates the expression of genes associated with the endoplasmic reticulum stress, p53-induced apoptosis, while increasing the expression of genes involved in the regulation of the cell cycle, DNA damage repair, cytokine signaling, nucleotide synthesis, PI3K/mTOR pathway and AMPK pathway in PL-MSCs under oxidative stress conditions. Taken together, the findings provide compelling evidence that fucoxanthin protects PL-MSCs against oxidative stress-induced apoptosis by modulating the expression of various genes involved in DNA damage repair, ER stress response, p53-induced apoptosis in these cells. This suggests that fucoxanthin could be used in combination with other agents to increase the therapeutic potential of MSCs by improving their viability under conditions of oxidative stress in the target tissue microenvironment. 2 2
Key numbers
101.82%
Increase in PL-MSC Viability
Viability of after treatment with 750 µM and 5 µM for 24 h.
75%
Decrease in
Viability of after 24 h of treatment with 750 µM .
14.39 ± 4.0 µM
Half-maximal Inhibitory Concentration (IC50)
IC50 of in after 24 h of treatment.
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: All experimental procedures were conducted under the Declaration of Helsinki and the Belmont Report. This study received approval from the Human Research Ethics Committee of Thammasat University (Medicine) under the title “Approval title: The effects of fucoxanthin on the proliferation and osteogenic differentiation of human mesenchymal stem cells.” (Approval number: 024/2021, Date of approval: February 4, 2021). All samples were obtained from donors who provided written informed consent. Consent for publication: Not applicable. Competing Interests: The authors declare that they have no competing interests.
